Replies to post #117840 on Biotech Values

[DSquared66]

Re: AMRN

Thanks for the post Jesse. I've been following (and buying on the way down) for a while now. I listened to the CEO's presentation yesterday and all seemed to be in order. Unfortunately, I don't have the science background to be able to read between the lines and verify that all that the company has put out is legitimate. Have you seen any scientific analysis beyond what you've posted?

From a safety profile perspective the fact that it's been available in Japan for so long may allay investors fears of hidden risk (of course being available in Japan has no impact as far as the FDA is concerned)

Has anyone else been following this story?

[DewDiligence]

Today’s AMR101 results would seem to undermine the premise for the fenofibrate drug class (TriCor/TriLipix). Comments?

[DFRAI]

Jessellivermore - if you have any

other visions or dreams about undervalued companies, please be more explicit about the urgency of such events. eh?

[DewDiligence]

JL et al re AMRN (in case you missed it):

http://www.nytimes.com/2011/05/03/health/research/03patterns.html

Men with the highest blood D.H.A. levels were 2.5 times more likely to develop high-grade, aggressive prostate cancer than those with the lowest D.H.A. levels, the researchers found. Another surprising finding was that men with the highest blood levels of trans fatty acids, which are harmful to the heart, had half the risk of aggressive prostate cancer compared with those who had the lowest levels. Both results confounded the scientists.

EPA can be converted to DHA in vivo, so this finding is potentially relevant to AMR101. The prostate-cancer finding could, of course, be a statistical fluke.